The economy might be sour, but Insogna said that many investors remain jazzed about opportunities in California.
"California, in my view, is a hot bed of life science companies, and there is lots of venture capital money still going into those companies - whether in clean tech, biotech or traditional pharmaceuticals developing new drugs," he said.
Among some of Insogna's significant deals over the past 18 months: He represented...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In